First Eagle Investment Management LLC lowered its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 55.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,282,326 shares of the company's stock after selling 4,060,248 shares during the quarter. First Eagle Investment Management LLC owned about 1.26% of Maravai LifeSciences worth $25,143,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in shares of Maravai LifeSciences by 0.9% in the 1st quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company's stock worth $12,069,000 after buying an additional 39,600 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Maravai LifeSciences by 64.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company's stock worth $4,015,000 after acquiring an additional 558,050 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Maravai LifeSciences in the second quarter worth $2,230,000. Russell Investments Group Ltd. boosted its holdings in Maravai LifeSciences by 4.9% in the third quarter. Russell Investments Group Ltd. now owns 166,243 shares of the company's stock worth $1,273,000 after acquiring an additional 7,699 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Maravai LifeSciences in the second quarter worth $1,038,000. Hedge funds and other institutional investors own 50.25% of the company's stock.
Maravai LifeSciences Stock Down 1.6%
Shares of MRVI opened at $7.28 on Wednesday. The business's 50 day moving average is $7.40 and its 200 day moving average is $5.46. The company has a market capitalization of $1.89 billion, a PE ratio of -16.93 and a beta of 0.61. Maravai LifeSciences Holdings, Inc. has a 12-month low of $2.80 and a 12-month high of $9.42. The company has a current ratio of 4.66, a quick ratio of 3.35 and a debt-to-equity ratio of 0.51.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03. The company had revenue of $45.85 million for the quarter, compared to the consensus estimate of $43.56 million. Maravai LifeSciences had a negative net margin of 30.83% and a negative return on equity of 12.44%. Research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.16 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the stock. Wells Fargo & Company upped their price target on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an "overweight" rating in a research note on Friday, August 7th. TD Cowen began coverage on shares of Maravai LifeSciences in a research note on Monday, October 5th. They set a "buy" rating and a $9.00 price objective for the company. UBS Group lifted their target price on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the stock a "neutral" rating in a report on Wednesday, September 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Finally, Wall Street Zen upgraded shares of Maravai LifeSciences from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $8.10.
Read Our Latest Report on Maravai LifeSciences
Maravai LifeSciences Company Profile
(
Free Report)
Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.